AI Article Synopsis

  • Sarcopenia, a syndrome linked to negative post-surgery outcomes, was studied to assess its impact on surgical site infections (SSIs) in colorectal cancer surgeries.
  • The study included 209 patients, finding no significant correlation between sarcopenia and the occurrence of SSIs, though 22% of patients experienced SSIs post-operation.
  • The only identified risk factor for SSIs was the non-laparoscopic approach to surgery, emphasizing the need for further research to minimize SSI rates in colorectal surgery.

Article Abstract

Sarcopenia is a syndrome that can be associated with unfavorable outcomes after colorectal cancer surgical procedures. The present study evaluates the relationship between sarcopenia and surgical site infections (SSIs) that can occur after colorectal cancer operations and that are a significant cause of morbidity. The research was designed as a retrospective study in which data were collected on patients who underwent colorectal cancer surgical procedures between January 2013 and July 2019. A diagnosis of sarcopenia was established based on the skeletal muscle index (SMI), calculated from pre-operative computed tomography scans. The SSI scores of patients with sarcopenia (sarcopenic group, SG) and those without sarcopenia (non-sarcopenic group, NSG) were compared, and a logistic regression analysis was performed to determine the risk factors for SSI. A total of 209 patients with a mean age of 61.2 years were included in the study. Post-operative complications (Clavien-Dindo ≥1) developed in 97 (46.4%) patients, SSIs developed in 46 (22%) patients, and sarcopenia developed in 97 (46.4%) patients. The mean age was 64.8 years in the SG group and 58.1 years in the NSG group (p = 0.016). No significant relationship was found between the development of SSI and sarcopenia (20 (20.6%) patients in the SG vs. 26 (23.2%) patients in the NSG, p = 0.65). Those in whom superficial SSIs developed in the early period formed the largest group (20 patients). The most commonly detected micro-organism was with a rate of 55%. In a multi-variable logistic regression analysis, only the non-laparoscopic approach was identified as a risk factor (odds ratio 3.83; 95% confidence interval 1.26-11.58; p = 0.017). The present study reports no relationship between sarcopenia and SSI after colorectal cancer operations. The authors consider that studies that endeavor to reduce the incidence of SSI, as a significant cause of morbidity after colorectal surgical procedures, should be supported.

Download full-text PDF

Source
http://dx.doi.org/10.1089/sur.2019.285DOI Listing

Publication Analysis

Top Keywords

colorectal cancer
20
surgical procedures
16
relationship sarcopenia
12
cancer surgical
12
patients
10
sarcopenia surgical
8
surgical site
8
sarcopenia
8
cancer operations
8
patients sarcopenia
8

Similar Publications

KRAS is a proto-oncogene that is found to be mutated in 15% of all metastatic cancers with high prevalence in pancreatic, lung, and colorectal cancers. Additionally, patients harboring KRAS mutations respond poorly to standard cancer therapy. As a result, KRAS is seen as an attractive target for targeted anticancer therapy.

View Article and Find Full Text PDF

Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.

View Article and Find Full Text PDF

This study evaluated the antioxidant and antiproliferative effects of aqueous, ethanolic and methanolic extracts of Sedum nicaeense flowers and leaves. The MTT assay assessed cytotoxicity against colorectal cancer cells (Caco-2, HCT-116), breast cancer cells (T47D, MCF-7) and normal fibroblasts (MRC-5), while the ferric-reducing antioxidant power (FRAP) assay measured antioxidant capacity. Essential oils from flowers and leaves were analyzed using gas chromatography-mass spectrometry (GC-MS).

View Article and Find Full Text PDF

Atractylenolide I (ATL-I) can interfere with Colorectal cancer (CRC) cell proliferation by changing apoptosis, glucose metabolism and other behaviors, making it an effective drug for inhibiting CRC tumor growth. In this paper, we investigated the interactions between ATL-I and Keratin 7 (KRT7), a CRC-specific marker, to determine the potential pathways by which ATL-I inhibits CRC development. The KRT7 expression level in CRC was predicted online using the GEPIA website and then validated.

View Article and Find Full Text PDF

Targeting KRAS: from metabolic regulation to cancer treatment.

Mol Cancer

January 2025

Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, 100191, China.

The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored the role of metabolic alterations in KRAS-driven cancers, providing a scientific rationale for targeting metabolism in cancer treatment. The development of KRAS-specific inhibitors has also garnered considerable attention, partly due to the challenge of acquired treatment resistance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!